IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis.
Despite the development of newer generation of antibiotics, mortality from neonatal sepsis remains high. In a prospective, randomized study, we investigated the use of IgM-enriched immunoglobulin therapy in neonatal sepsis. Two groups of 30 infants each (matched for gestational age, sex, weight, and other variables) were randomly allocated to receive either antibiotics alone (control group) or antibiotics plus 5 mL/kg/d for four days of IgM-enriched immunoglobulin intravenously (immunotherapy group). Mortality from sepsis in the control group was 20% (6/30), while in the immunotherapy group it was 3.3% (1/30). We conclude that IgM-enriched immunoglobulin therapy in conjunction with antibiotic therapy significantly reduces mortality from neonatal sepsis.
Haque
K N
KN
Department of Paediatrics, College of Medicine, Riyadh, Saudi Arabia.
Zaidi
M H
MH
Bahakim
H
H
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007075:Immunoglobulin M / Q000627:therapeutic use*; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy / Q000628:therapy*; D007262:Infusions, Intravenous; D008020:Life Support Care; D008297:Male; D011897:Random Allocation
D000900:Anti-Bacterial Agents; D007075:Immunoglobulin M